Table 3.

Multivariate analysis of factors associated with overall survival and disease progression in TNM stage III–IV (n = 41).

	Overall survival			Disease progression
	Univariate	Multivariate		Univariate	Multivariate
	P value	P value	Hazard ratio (95% CI)	P value	P value	Hazard ratio (95% CI)
Previous HCC treatment history	.044			.084
Size of tumor, cm (≥5 vs <5)	.003	.011	3.959 (1.367–11.467)	.007	.075
PVT	.007	.004	3.531 (1.487–8.387)	.038	.021	3.185 (1.188–8.535)
N stage	.004	.004	17.653 (2.558–121.812)	.006	<.001	56.026 (6.772–463.505)
M stage	.202			.056
Performance status	.016			.017	.003	11.935 (2.387–59.683)
CRP, mg/dL	.001			<.001
Aspartate aminotransferase, IU/L	.033			.01	.003	1.019 (1.006–1.031)
Presence of ascites	.014	.001	41.993 (4.853–363.401)	.016	<.001	156.833 (12.930–1902.309)
LINE-1 hypomethylation	.404	.027	4.216 (1.179–15.074)	.437	.006	7.519 (1.774–31.864)